REG - PureTech Health PLC - PRTC Presents at Jefferies Healthcare Conference

Puretech HealthAnnouncement

09/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211109:nRSI7256Ra&default-theme=true

RNS Number : 7256R  PureTech Health PLC  09 November 2021

9 November 2021

PureTech Health plc

 

PureTech Announces Participation at the Jefferies London Healthcare Conference

 

Company reports PureTech Level Cash and Cash Equivalents of $387.3 million(1)
and Consolidated Cash and Cash Equivalents of $441.0 million(2) as of
September 30, 2021

 

PureTech Health plc (https://www.puretechhealth.com/) (Nasdaq: PRTC, LSE:
PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company
dedicated to discovering, developing and commercializing highly differentiated
medicines for devastating diseases, today announced that Bharatt Chowrira,
Ph.D., J.D., President and Chief of Business and Strategy, and George Farmer,
Ph.D., Chief Financial Officer, will participate in a fireside chat at the
Jefferies London Healthcare Conference on Wednesday, November 17, 2021, at
7:20 AM EST. A webcast of the presentation will be available at
https://investors.puretechhealth.com/events-presentations
(https://investors.puretechhealth.com/events-presentations) .

 

Additionally, the Company reported PureTech Level Cash and Cash Equivalents of
$387.3 million and Consolidated Cash and cash equivalents of $441.0 million as
of September 30, 2021.(3) PureTech's Founded Entities are also
well-capitalized, having raised over $1.6 billion since July 2018, 96% of
which came from third-party investors.(4)

 

Non-IFRS Financial Measures

PureTech Level Cash and Cash Equivalents is an alternative performance measure
which is adjusted and constitutes a non-IFRS measure. We believe that these
non-IFRS performance measures, when provided in combination with IFRS
measures, will provide investors, analysts and other stakeholders with helpful
complementary information to better understand our financial position from
period to period. The measures are also used by management for planning and
reporting purposes. The measures are not substitutable for IFRS measures and
should not be considered superior to measures presented in accordance with
IFRS.

 

PureTech Level Cash and Cash Equivalents is defined as cash and cash
equivalents held at PureTech Health plc and its wholly-owned subsidiaries
only. Please see below for a reconciliation to Consolidated Cash and cash
equivalents, which is the most directly comparable measure calculated in
accordance with IFRS.

 

 (in thousands)                                                         As of September 30, 2021
 Consolidated Cash and cash equivalents                                 $440,966
 Less: Cash and cash equivalents held at non-wholly owned subsidiaries  ($53,648)
 PureTech Level Cash and Cash Equivalents                               $          387,318

 

1.     PureTech Level Cash and Cash equivalents as of September 30, 2021
represent cash and cash equivalents held at PureTech Health plc and its
wholly-owned subsidiaries only. Please see the section captioned "Non-IFRS
Financial Measures" included in this release for additional information.

2.     Consolidated Cash and cash equivalents as of September 30, 2021
represent cash and cash equivalents for PureTech Health plc in accordance with
International Financial Reporting Standards (IFRS). Please see the section
captioned "Non-IFRS Financial Measures" included in this release for
additional information.

3.     These figures are unaudited and do not present all information
necessary for an understanding of the Company's financial condition as of
September 30, 2021.

4.     Funding figure includes private equity financings, loans and
promissory notes, public offerings, or grant awards. Funding figure excludes
future milestone considerations received in conjunction with partnerships and
collaborations such as with, Boehringer Ingelheim, Imbrium Therapeutics L.P.,
Shionogi & Co Ltd, or Eli Lilly.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering,
developing and commercializing highly differentiated medicines for devastating
diseases, including inflammatory, fibrotic and immunological conditions,
intractable cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has created a
broad and deep pipeline through the expertise of its experienced research and
development team and its extensive network of scientists, clinicians and
industry leaders. This pipeline, which is being advanced both internally and
through PureTech's Founded Entities, is comprised of 25 therapeutics and
therapeutic candidates, including two that have received both U.S. FDA
clearance and European marketing authorization, as of the date of PureTech's
most recently filed Half Year Report and corresponding Form 6-K. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points based on the
Company's unique insights into the biology of the brain, immune and gut, or
BIG, systems and the interface between those systems, referred to as the BIG
Axis.

 

For more information, visit www.puretechhealth.com or connect with us on
Twitter @puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including, without limitation, our participation in upcoming events and
presentations. The forward-looking statements are based on current
expectations and are subject to known and unknown risks, uncertainties and
other important factors that could cause actual results, performance and
achievements to differ materially from current expectations, including, but
not limited to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on Form 20-F
for the year ended December 31, 2020 filed with the SEC and in our other
regulatory filings. These forward-looking statements are based on assumptions
regarding the present and future business strategies of the Company and the
environment in which it will operate in the future. Each forward-looking
statement speaks only as at the date of this press release. Except as required
by law and regulatory requirements, we disclaim any obligation to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.

 

 Contact:

 Investors                EU media
 Allison Mead Talbot      Ben Atwell, Rob Winder

 +1 617 651 3156          +44 (0) 20 3727 1000

 amt@puretechhealth.com   ben.atwell@FTIconsulting.com

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZMGMMRKGMZZ